Sandoz steps up in-house biosimilar capabilities

Switzerland-based Sandoz (SIX: SDZ), a leader in affordable medicines, today inaugurated a new biosimilar development center in Ljubljana, Slovenia, to strengthen and expand its in‑house biosimilar capabilities.

Gilbert Ghostine, Sandoz’ chairman, says: “As we mark 20 years since the world’s first biosimilar, we are proud of the pioneering role Sandoz has played in expanding patient access to therapies that treat complex conditions. Today, with the opening of our new biosimilar development centre, we are investing in the future, harnessing science and capabilities to bring high‑quality biosimilars to patients faster and more affordably, while supporting the sustainability of healthcare systems.”